A prospective observational study in fibrotic interstitial lung disease evaluated CMR-derived pulmonary artery peak flow velocity as a marker for severe pulmonary hypertension. The work reported a strong association with invasively measured pulmonary vascular resistance and effective discrimination between severe and non-severe disease. For clinical decision-making in fibrotic ILD, the signal supports a noninvasive imaging route that may help triage patients for catheter-based assessment. The finding also aligns with growing interest in multimodal, imaging-derived biomarkers to reduce reliance on invasive testing.